Literature DB >> 15555916

Peripheral myelin protein 22 kDa and protein zero: domain specific trans-interactions.

Birgit Hasse1, Frank Bosse, Helmut Hanenberg, Hans Werner Müller.   

Abstract

The peripheral myelin proteins P0 and PMP22 are associated in preparations of compact myelin and in cell cultures coexpressing both molecules. The mechanism of this interaction, however, still needs to be unravelled. We have established three different (cell-cell, cell-protein, protein-protein based) assay systems using retrovirally transduced HeLa cells that overexpressed either PMP22 or P0 and purified GST fusion oligopeptides of PMP22 and P0 to detect domain-specific interactions between these proteins. The results revealed that PMP22 and P0 are involved in both trans-homophilic and trans-heterophilic interactions. Moreover, the data clearly indicate that the heterophilic trans-interaction is mediated through the second loop of PMP22, while the first loop is involved in homophilic trans-interaction of PMP22 proteins. Both modes of interaction are due to direct protein-protein binding. In addition, we demonstrate that disease-related point mutations of P0 resulted in a decreased adhesion capability correlating with the severity of the respective disease phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555916     DOI: 10.1016/j.mcn.2004.06.009

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  16 in total

Review 1.  Myelin disorders: Causes and perspectives of Charcot-Marie-Tooth neuropathy.

Authors:  Gerd Meyer zu Hörste; Thomas Prukop; Klaus-Armin Nave; Michael W Sereda
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice.

Authors:  Sunitha Rangaraju; Jonathan D Verrier; Irina Madorsky; Jessica Nicks; William A Dunn; Lucia Notterpek
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

3.  A dual role for Integrin α6β4 in modulating hereditary neuropathy with liability to pressure palsies.

Authors:  Yannick Poitelon; Vittoria Matafora; Nicholas Silvestri; Desirée Zambroni; Claire McGarry; Nora Serghany; Thomas Rush; Domenica Vizzuso; Felipe A Court; Angela Bachi; Lawrence Wrabetz; Maria Laura Feltri
Journal:  J Neurochem       Date:  2018-02-13       Impact factor: 5.372

4.  Peripheral myelin protein 22 is in complex with alpha6beta4 integrin, and its absence alters the Schwann cell basal lamina.

Authors:  Stephanie A Amici; William A Dunn; Andrew J Murphy; Niels C Adams; Nicholas W Gale; David M Valenzuela; George D Yancopoulos; Lucia Notterpek
Journal:  J Neurosci       Date:  2006-01-25       Impact factor: 6.167

Review 5.  Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease.

Authors:  Axel Niemann; Philipp Berger; Ueli Suter
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 6.  Animal models of Charcot-Marie-Tooth disease type 1A.

Authors:  M W Sereda; K-A Nave
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 7.  Mechanisms and Treatments in Demyelinating CMT.

Authors:  Vera Fridman; Mario A Saporta
Journal:  Neurotherapeutics       Date:  2021-11-08       Impact factor: 6.088

Review 8.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

9.  PMP22 expression in dermal nerve myelin from patients with CMT1A.

Authors:  Istvan Katona; Xingyao Wu; Shawna M E Feely; Stephanie Sottile; Carly E Siskind; Lindsey J Miller; Michael E Shy; Jun Li
Journal:  Brain       Date:  2009-05-15       Impact factor: 13.501

10.  Glycosylation Limits Forward Trafficking of the Tetraspan Membrane Protein PMP22.

Authors:  Justin T Marinko; Madison T Wright; Jonathan P Schlebach; Katherine R Clowes; Darren R Heintzman; Lars Plate; Charles R Sanders
Journal:  J Biol Chem       Date:  2021-04-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.